Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study (Q45274588)
scientific article
Language:
Current Data About Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study
(P31) (Q13442814)
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P304) 749-752
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P407) (Q1860)

(P433) 3
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P478) 96
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P577) Tuesday, March 1, 2005
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P921) (Q18936)
(P887)

(Q5625186)
(P887)

(Q1504713)
(P887)

(P1433) (Q5625182)
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P1476) "Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study" (language: en)
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P2093) Gregory Sutton
(P1545) 1
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

John Blessing
(P1545) 2
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

Parviz Hanjani
(P1545) 3
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

Paul Kramer
(P1545) 4
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

Gynecologic Oncology Group
(P1545) 5
(P248)
(P698) 15721421
(P813) Monday, December 11, 2017

(P2860) (Q34546077)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q36742644)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q68134695)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q42247369)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q69885772)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q70024252)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q68043717)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q33362563)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q33496577)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q33329965)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q35650600)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

(Q33342842)
(P248)
(P854) https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036
(P813) Thursday, January 7, 2021

other details
description scientific article

External Links
(P356) 10.1016/J.YGYNO.2004.11.036
(P698) 15721421
(P5875) 8012831